688131 皓元医药
2026/06 - 中期
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入1,647,97425.71%2,876,8962,270,1781,880,0471,358,054
减:营业总成本1,384,31927.73%2,442,4691,900,8821,672,7071,144,721
    其中:营业成本811,40121.53%1,521,7761,181,2791,030,874659,411
               财务费用69,968319.24%63,03434,51631,850(578)
               资产减值损失(79,887)31.03%(134,088)(131,360)(83,999)(43,376)
公允价值变动收益28333.00%74150----
投资收益311-75.06%(15,967)(13,758)(4,772)16,053
    其中:对联营企业和合营企业的投资收益(2,534)-37.18%(8,514)(13,771)(6,113)(2,746)
营业利润193,5284.77%296,753236,817128,329196,567
利润总额192,5936.04%275,776238,355128,193198,543
减:所得税费用30,497-7.38%44,13040,4251,8856,986
净利润162,0969.01%231,645197,930126,308191,558
减:非控股权益(9,104)197.03%(8,161)(3,660)(1,142)(2,086)
股东净利润171,20012.81%239,807201,590127,449193,643

市场价值指针
每股收益 (元) *0.81012.50%1.1300.9600.6101.330
每股派息 (元) *0.09012.50%0.2300.1900.1500.380
每股净资产 (元) *15.1028.76%14.34313.10916.68421.690
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容